CD163

CD163 Molekülinformation

Englischer Name	Scavenger receptor cysteine-rich type 1 protein M130	Anzahl der inverkehr gebrachten Arzneimittel	1
Anzahl der klinischen Arzneimittel	1	Target-Alias	CD163，M130，Scavenger receptor cysteine-rich type 1 protein M130，sCD163，CD163 Molecule，Hemoglobin Scavenger Receptor，CD163 Antigen，Macrophage-Associated Antigen，SCARI1，MM130
Höchste Forschungs- und Entwicklungsphase	Approved

Englischer Name	Scavenger receptor cysteine-rich type 1 protein M130
Target-Alias	CD163，M130，Scavenger receptor cysteine-rich type 1 protein M130，sCD163，CD163 Molecule，Hemoglobin Scavenger Receptor，CD163 Antigen，Macrophage-Associated Antigen，SCARI1，MM130
Anzahl der inverkehr gebrachten Arzneimittel	1
Anzahl der klinischen Arzneimittel	1
Höchste Forschungs- und Entwicklungsphase	Approved

CD163 Produktliste

Attribut
Protein (1)
Produktbibliothek
Online (1)
Spezies
Human (1)
Etikett
His Tag (1)
Marker
Unconjugated (1)

Produktnummer	Spezies	Expressionssystem	Produktbeschreibung	Proteinstruktur	Reinheit	Eigenschaften	Vorbestellen/Bestellen
CD3-H52E8	Human	HEK293	Human CD163 Protein, His Tag				In den Warenkorb legen

Gesamtmenge1

CD163 Molekülhintergrund

Scavenger receptor cysteine-rich type 1 protein M130 (CD163) is also known as hemoglobin scavenger receptor, which is a scavenger receptor for the hemoglobin-haptoglobin complex. CD163 has also been shown to mark cells of monocyte/macrophage lineage. A soluble form of the receptor exists in plasma, commonly denoted sCD163. sCD163 is generated by ectodomain shedding of the membrane bound receptor. sCD163 is upregulated in a large range of inflammatory diseases including liver cirrhosis, type 2 diabetes, macrophage activation syndrome, Gaucher's disease, sepsis, HIV infection, rheumatoid arthritis and Hodgkin Lymphoma.

CD163 Molekülalias

CD163,M130

Klinische Arzneimittelinformation

Englischer Name	Forschungscode	Forschungsphase	Firma	Indikationen	Klinische Studie
OR-2805	OR-2805	Phase 2 Clinical	OncoResponse Inc	Carcinoma, Non-Small-Cell Lung; Leiomyosarcoma; Liposarcoma; Melanoma; Neoplasm Metastasis; Neoplasms; Solid tumours; Squamous Cell Carcinoma of Head and Neck	Details

Inverkehr gebrachte Arzneimittelinformation

Englischer Name	Forschungscode	Forschungsphase	Firma	Frühestes Markenname	Frühestes Genehmigungsland	Früheste Indikation	Früheste Genehmigungsgesellschaft	Früheste Genehmigungsdatum	Indikationen	Klinische Studie
Tetrachlorodecaoxide	OXO-K993; WF-10; TCDO	Approved	Nuvox Pharma LLC	Oxoferin, Immunokine, WF10	Thailand	Inflammation; Rhinitis, Allergic	null	1997-01-01	Diabetic Foot; HIV Infections; Inflammation; Rhinitis, Allergic	Details